[A22-105] Difelikefalin (pruritus) - Benefit assessment according to §35a Social Code Book V

Last updated 02.01.2023

Project no.:
A22-105

Commission:
Commission awarded on 04.10.2022 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Skin and hair

Indication:

adult haemodialysis patients with moderate to severe chronic kidney disease–associated pruritus (CKD-aP)

Result of dossier assessment:

added benefit not proven

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form